Savara (NASDAQ:SVRA) Price Target Lowered to $6.00 at HC Wainwright

Savara (NASDAQ:SVRA) had its target price reduced by HC Wainwright from $10.00 to $6.00 in a report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities analysts have also commented on SVRA. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research note on Wednesday. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Savara presently has an average rating of “Moderate Buy” and an average price target of $10.17.

Savara Price Performance

Shares of SVRA stock opened at $3.25 on Wednesday. The business’s 50-day moving average price is $3.96 and its 200-day moving average price is $4.22. Savara has a 12 month low of $3.24 and a 12 month high of $5.70. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, equities analysts expect that Savara will post -0.44 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Several hedge funds and other institutional investors have recently modified their holdings of the company. CANADA LIFE ASSURANCE Co bought a new stake in Savara during the first quarter worth $35,000. Choreo LLC bought a new stake in Savara during the second quarter worth $59,000. DRW Securities LLC bought a new stake in Savara during the second quarter worth $62,000. Principal Financial Group Inc. grew its holdings in Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC bought a new stake in Savara during the second quarter worth $105,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.